Pharmaceutical companies each make big moves to be shortlisted for the health insurance catalog

, the hot sun grills the earth. It's not just the weather that's hot. A campaign to prepare for the entry into the national new health insurance catalog, began in the anti-cancer drug companies in full swing.April this year, the National Health Insurance Administration has published the 2019 National Health Insurance Directory Adjustment Work Programme (hereinafter referred to as the "Work Programme"). This round of medical insurance catalog adjustment, including drug transfer and drug transfer out of two content. At the same time, priority has been given to key national essential medicines, cancer and rare diseases, children's medicines and other key varieties. This for the relevant anti-cancer drug companies, undoubtedly means ushering in new opportunities for development. Once shortlisted, it will make it easier to reach the end-hospital market while improving drug access.Ant-cancer drug enterprise preparation work programme shows that the entire drug catalog adjustment has been initiated since the beginning of the year, divided into preparation, review, release of regular access directory, negotiation, release of negotiation access directory 5 stages. At this point, we are in the drug catalog adjustment review phase, which will continue until July.Recently, the reporter was informed that Baiji Shenzhou obtained the new base authorized to sell products in China - Kessin Abraxane (injection with yew alcohol, nano albumin particle binding type, referred to as albumin yew alcohol), plans to complete the national price reduction in mid-2019, from 5510 yuan / 100mg to 3350 yuan / 100mg, a decrease of 39%. By the end of April 2019, the drug had also been reduced in 12 provinces.price cuts in the U.S. state of Shenzhou in an effort to support the health-care catalog."We took the initiative to reduce prices, mainly in view of the fact that we bought the commercial interest in China, we have autonomy. On the other hand, albumin yew alcohol performs well clinically and is currently the only FDA-approved yew drug capable of combining immunological agents (PD-1/L1) to treat breast cancer. We'd rather sacrifice some profits than benefit more people before we get health insurance. We're also ready to get into health care. Wu Xiaobin, general manager and president of Baiji Shenzhou China, told reporters."Some of the more expensive cancer drugs may make the necessary price cuts in order to gain access to health care. Because the health insurance catalog in the selection process, the economics of drugs is an important consideration. A pharmaceutical company in Jiangsu told reporters.albumin yew alcohol is an improved product of the star anti-cancer drug yew alcohol. Yew alcohol is a cornerstone of the standard treatment for breast cancer, but the toxicity of drug solvents has been a huge obstacle to the progress of breast cancer treatment. The emergence of albumin yew alcohol has brought new breakthroughs in the field of breast cancer treatment. The above-mentioned product, Kessin, was approved for sale in China in 2008 to treat metastasis breast cancer, which fails with combined chemotherapy, or breast cancer that relapses within 6 months after complementary chemotherapy.There are also industry sources told reporters that Baiji Shenzhou in advance to choose to reduce prices, should also take into account the current fierce competition in the albumin yew alcohol market, in addition to Baiji Shenzhou, there are Hengrui Pharmaceuticals, Stone Pharmaceutical Group and other manufacturers are also involved in the market.the current initiative to reduce the price of products, and not only Baiji Shenzhou one. Heavy bio-innovative drug Edo, which was approved for sale last year, has also cut prices. Company insiders told reporters that the early price reduction, but also hope to be able to follow into the national health care directory.in addition to choosing to cut prices directly, drug companies are starting to vote for their star new drugs on social media. For example, Sanofi, the treatment of rare disease multiple sclerosis "Opatier" and the treatment of non-Hodgkin's lymphoma "relief", are the company in the past year, approved in China's new drug market. The company is calling on social media to support the two drugs' access to the National Health Insurance Directory, and has developed posters to that end.immunotherapy anti-cancer drug PD-1, is currently the star of the market anti-cancer drugs, will not next enter the national health insurance directory, also attracted market attention. Unlike traditional chemotherapy drugs and targeted drugs, the emergence of PD-1 has made it possible to cure tumors. Up to now, including imports, domestic, a total of 4 PD-1 has been approved for listing in China. However, each drug is expensive, and the cost of a year's treatment can reach tens of thousands of years."We will respond to the call of the state to actively participate in this dynamic adjustment of the national health insurance directory to make PD-1 drugs more accessable." As one of the domestic PD-1 manufacturers - Junshi biological related person in charge of such a reply to reporters.National opportunities brought about by the adjustment of the medical insurance catalogue As the largest payer of China's pharmaceutical market, the importance of drug release is self-evident, especially for the more expensive innovative drugs, included in the medical insurance catalog, on the one hand, can reduce the burden of patients, on the other hand, also increase the willingness of hospitals to use drugs.shen Wanhongyuan statistics show that the last round of 2017 medical insurance catalog adjustment, the pull effect of health insurance on drug release is more significant. The specific performance is that into the 2017 edition of the general list of health insurance varieties, expensive and in the release period of the varieties increased significantly. Sales in 2018 were up 113% year-on-year, and in 2018 at Beda Pharmaceuticals' Ektini, sales were up 45% year-on-year. At the same time, most of the varieties entering the health care negotiations have also increased significantly in sales and sales in 2018. Sales in 2018 will increase by 259% year-on-year after Roche's Quto Zhu single-resistance, which cut prices by 65%.Shen Wanhongyuan also said in the study that historically, since its release in 2000, the National Health Insurance Directory has under only under three major adjustments, in 2004, 2009 and 2017. However, due to the long adjustment interval, many innovative varieties after the market failed to catch up with the health care adjustment, and therefore also missed the opportunity to release.round of health-care directory adjustments, launched in 2019, is the first time since the new establishment of the National Health Insurance Administration to make a systematic adjustment to the national health-care directory. Compared to the last round of 2017, the time interval is only two years. The industry tends to believe that with this round of health insurance catalog adjustment, the future health insurance catalog adjustment is expected to achieve normalization. This will undoubtedly contribute to the development of innovative medicines. 　　"As far as we can expect, the first wave of health care negotiations and selection will probably take place by the end of September as part of this year's health-care catalog adjustment. We hope that the health care directory can be adjusted on a regularly, especially cancer medicine, which is a life-saving drug, and that in the past health care negotiations have been too long for patients to be treated in a timely manner. If the health insurance catalogue establishes a dynamic adjustment mechanism, some drugs with particularly significant efficacy and better economy can enter the market quickly. Wu Xiaobin told reporters. This round of medical insurance catalog adjustment, including drug transfer and drug transfer out of two content, transfer into the two ways of regular access and negotiated access, in order to meet the validity, safety and other premises, the price (cost) and the existing varieties in the drug catalog is comparable or low, can be included in the list in the regular way; industry is also watching to see which drugs are expected to be included in the new national health-care directory. In Guotai Junan Securities' view, the clinical effects of varieties (especially compared to those already in the current catalogue), price conditions (drug economics) and competitive patterns (with targets or therapeutic areas) will be key factors in determining whether varieties can eventually be included in health insurance and price reductions. 　　"There are reference, or overpriced varieties, in order to be able to enter the regular health insurance directory, will choose to take the initiative to cut prices in advance." Hengrui Pharmaceuticals said the above-mentioned executives told reporters. 　　"It's certainly best not to cut prices, but at this point we're going to reflect the value of the product through a variety of studies." A multinational pharmaceutical company also told reporters. (First Finance)